Cardiovascular drug might treat diabetic retinopathy
October 1st 2008A drug that has traditionally been used to treat cardiovascular conditions has shown promise in the treatment and prevention of diabetic retinopathy. The claim was based on data from a large-scale programme assessing the effect of an angiotensin receptor blocker (ARB) on the incidence and progression of diabetic eye disease. Findings from the study will be published in The Lancet.
UK reimburses Lucentis… at last!
October 1st 2008The UK's medical reimbursement governing body, the National Institute for Health and Clinical Excellence (NICE), is to reimburse Lucentis (ranibizumab; Novartis) jointly with Novartis under a dose-capping scheme, reversing NICE's earlier, much derided, decision not to reimburse the drug.
ROP treatment proves its worth
September 29th 2008Intravenous administration of IPLEX, Insmed Inc's rhIGF-I/rhIGFBP-3 complex, is well-tolerated and efficacious in significantly premature infants, according to Phase I study results announced at this year's European Society for Paediatric Endocrinology meeting, held 20?23 September in Istanbul, Turkey.
Good VA means good stereopsis in children
September 29th 2008Postoperative visual acuity (VA) is the factor with the most significant impact on stereopsis in paediatric unilateral pseudophakic subjects, according to study results published online ahead of print by the British Journal of Ophthalmology.